AMTD Assisted Aptorum Group's NASDAQ IPO

AMTD Group announced the completion of the US IPO of Aptorum Group Limited on the NASDAQ Stock Exchange, which occurred on December 18, 2018. AMTD acted as a Joint Bookrunner for the offering.

Aptorum Group is a Hong Kong-based biopharmaceutical company focused on developing and commercializing medical innovations. The company's pipeline includes therapeutic and diagnostic projects targeting unmet medical needs in areas such as neurology, infectious diseases, and oncology. They also have projects in surgical robotics and operate a medical clinic.

This listing represented AMTD's fifth US IPO in 2018, underscoring the firm's role in facilitating international capital market access for Asian companies. Throughout that year, AMTD was involved in numerous other IPOs for Chinese technology firms on major US exchanges.

As a comprehensive financial institution rooted in Hong Kong, AMTD focuses on providing diversified financial services and aims to assist companies, particularly in Asia, with their global development strategies. The firm has a history of advising on capital market transactions, including IPOs for various sectors and bond issuances.